title: Mean intraocular pressure and progression based on corneal thickness in patients with ocular hypertension.
abstract: OBJECTIVE
  To determine the incidence of glaucomatous progression at mean intraocular pressure (IOP) levels in patients with ocular hypertension (OHT).
  
  
  METHODS
  A retrospective, multicentre, cohort analysis of 230 OHT patients with 5 years of follow-up evaluated for risk factors associated with progressive optic disc and visual field loss to determine the incidence of glaucomatous progression.
  
  
  RESULTS
  Forty percent of patients with IOPs > or = 24 mmHg, 18% of patients with IOPs of 21-23 mmHg, 11% of patients with IOPs with 18-20 mmHg, and 3% of patients with IOPs of < or = 17 mmHg progressed to glaucoma. The mean IOP was 19.8+/-2.4 mmHg in the stable group and 21.7+/-2.6 mmHg in the progressed group (P=0.0004). The highest average peak IOP was 23.4+/-4.0 mmHg in the stable group and 25.2+/-3.1 mmHg in the progressed group (P=0.006). Based on the pachymetry values for central corneal thickness, patients with thinner corneas more often progressed to glaucoma (P<0.0001). A multivariant regression analysis to determine risk factors for progression was positive primarily for higher peak IOPs, older age, male gender, argon laser trabeculoplasty, visual acuity > or = 20/50, and no topical medical therapy or beta-blocker therapy prior to the study.
  
  
  CONCLUSIONS
  IOP reduction within the normal range over 5 years of follow-up reduces the chance of progression to primary open-angle glaucoma in OHT patients.
authors.affiliation: AHEPA Hospital, Thessaloniki, Greece.
authors.forename: A G P
authors.initials: AG
authors.lastname: Konstas
authors.forename: M T
authors.initials: MT
authors.lastname: Irkec
authors.forename: M A
authors.initials: MA
authors.lastname: Teus
authors.forename: B
authors.initials: B
authors.lastname: Cvenkel
authors.forename: Y S
authors.initials: YS
authors.lastname: Astakhov
authors.forename: E D
authors.initials: ED
authors.lastname: Sharpe
authors.forename: G
authors.initials: G
authors.lastname: Hollo
authors.forename: N
authors.initials: N
authors.lastname: Mylopoulos
authors.forename: B
authors.initials: B
authors.lastname: Bozkurt
authors.forename: C
authors.initials: C
authors.lastname: Pizzamiglio
authors.forename: V V
authors.initials: VV
authors.lastname: Potyomkin
authors.forename: A M
authors.initials: AM
authors.lastname: Alemu
authors.forename: Q J
authors.initials: QJ
authors.lastname: Nasser
authors.forename: J A
authors.initials: JA
authors.lastname: Stewart
authors.forename: W C
authors.initials: WC
authors.lastname: Stewart
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D003315:Cornea / Q000033:anatomy & histology*; D018450:Disease Progression; D005260:Female; D005901:Glaucoma / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000473:pathology / Q000503:physiopathology*; D012044:Regression Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D014130:Trabeculectomy / Q000706:statistics & numerical data; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D000319:Adrenergic beta-Antagonists